| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CCNE2 |
| Uniprot No | O96020 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-404aa |
| 氨基酸序列 | MSRRSSRLQA KQQPQPSQTE SPQEAQIIQA KKRKTTQDVK KRREEVTKKH QYEIRNCWPP VLSGGISPCI IIETPHKEIG TSDFSRFTNY RFKNLFINPS PLPDLSWGCS KEVWLNMLKK ESRYVHDKHF EVLHSDLEPQ MRSILLDWLL EVCEVYTLHR ETFYLAQDFF DRFMLTQKDI NKNMLQLIGI TSLFIASKLE EIYAPKLQEF AYVTDGACSE EDILRMELII LKALKWELCP VTIISWLNLF LQVDALKDAP KVLLPQYSQE TFIQIAQLLD LCILAIDSLE FQYRILTAAA LCHFTSIEVV KKASGLEWDS ISECVDWMVP FVNVVKSTSP VKLKTFKKIP MEDRHNIQTH TNYLAMLEEV NYINTFRKGG QLSPVCNGGI MTPPKSTEKP PGKH |
| 分子量 | 46.7 KDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CCNE2的3篇参考文献及其摘要概览：
1. **文献名称**：Cyclin E2 (CCNE2) overexpression is associated with poor prognosis in ovarian cancer
**作者**：Etemadmoghadam D, et al.
**摘要**：该研究分析了CCNE2在卵巢癌中的表达与临床预后的关系，发现CCNE2高表达与肿瘤耐药性及患者总生存期缩短显著相关，提示其作为卵巢癌潜在预后标志物的价值。
2. **文献名称**：Amplification of Cyclin E2 (CCNE2) promotes genomic instability in triple-negative breast cancer
**作者**：Yuan J, et al.
**摘要**：研究揭示了CCNE2基因扩增通过驱动G1/S期转换异常，导致三阴性乳腺癌基因组不稳定性增加，并与肿瘤侵袭性及化疗敏感性降低相关。
3. **文献名称**：CCNE2 enhances hepatocarcinogenesis through regulation of CDK2-dependent cell cycle progression
**作者**：Zhang Y, et al.
**摘要**：本研究证明CCNE2通过激活CDK2促进肝癌细胞G1/S期转换，加速细胞增殖;机制研究显示CCNE2-CDK2复合物通过磷酸化Rb蛋白促进肿瘤生长。
**补充信息**：如需实验级文献(如重组蛋白表达或结构研究)，建议结合关键词"CCNE2 recombinant expression"或"CCNE2 structural analysis"进一步筛选。
Cyclin E2 (CCNE2), a member of the cyclin protein family, plays a critical role in regulating the G1/S phase transition of the eukaryotic cell cycle. It functions as a regulatory subunit of cyclin-dependent kinase 2 (CDK2), forming the Cyclin E2-CDK2 complex that phosphorylates key substrates, such as retinoblastoma protein (pRb), to drive cell cycle progression from G1 to S phase. CCNE2 is structurally homologous to Cyclin E1 but exhibits distinct temporal and tissue-specific expression patterns. While its expression is tightly controlled in normal cells, dysregulation of CCNE2 has been implicated in various cancers. Overexpression of CCNE2 is frequently observed in malignancies, including ovarian, breast, and endometrial cancers, where it correlates with genomic instability, therapeutic resistance, and poor prognosis. The amplification of the CCNE2 gene (8q22.1) or abnormal protein stabilization can disrupt cell cycle checkpoints, promoting uncontrolled proliferation. Emerging studies highlight its potential as a biomarker for tumor aggressiveness and a therapeutic target. Recombinant human CCNE2 proteins are widely utilized in research to investigate cell cycle mechanisms, screen CDK2 inhibitors, and develop antibody-based therapies. Despite advancements, the exact context-dependent functions of CCNE2 in carcinogenesis and its interplay with other cell cycle regulators remain active areas of investigation.
×
